We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MorphoSys and Pfizer’s Antibody Development Deal Expanded for Three Years

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys and Pfizer’s Antibody Development Deal Expanded for Three Years"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
MorphoSys has announced that it has expanded its collaboration with Pfizer for the development of antibody therapeutics by three years.
The agreement builds upon a deal struck in 2003 scheduled to end in 2008. The new deal extends the collaboration to 2011 and includes a one-off payment from Pfizer, MorphoSys said.
Under the agreement, MorphoSys, based in Martinsried, Germany, will use its HuCAL Gold human combinatory antibody library to generate therapeutic antibodies against targets supplied by Pfizer, which Pfizer will then take to preclinical and clinical trials.
MorphoSys said the agreement offers potential royalties and milestone payments from resulting product sales.
Financial terms of the agreement were not released.